【摘 要】
:
Objective: To identify healthcare managers\' perspectives on the barriers to implementing cervical length screening to prevent preterm births. Methods: In PhaseⅠ, 10 healthcare managers were interviewed. Phase Ⅱ comprised questionnaire development and d
【机 构】
:
Division of Maternal-Fetal Medicine,Department of Obstetrics and Gynaecology,Faculty of Medicine Sir
论文部分内容阅读
Objective: To identify healthcare managers\' perspectives on the barriers to implementing cervical length screening to prevent preterm births. Methods: In PhaseⅠ, 10 healthcare managers were interviewed. Phase Ⅱ comprised questionnaire development and data validation. In Phase Ⅲ, the questionnaire was administered to 40 participants, and responses were analyzed. Results: Their average related work experience was (21.0±7.2) years; 39 (97.5%) respondents also had healthcare management responsibilities at their respective hospitals. Most hospitals were reported to have enough obstetricians (31 cases, 77.5%) and to be able to accurately perform cervical length measurements (22 cases, 55.0%). However, no funding was allocated to universal cervical length screening (39 cases, 97.5%). Most respondents believed that implementing universal screening, as per Ministry of Public Health policies, would prevent preterm births (28 cases, 70.0%). Moreover, they suggested that hospital fees for cervical length measurements should be waived (34 cases, 85.0%). Three main perceived barriers to universal screening at tertiary hospitals were identified. They were heavy obstetrician workloads (20 cases, 50.0%); inadequate numbers of medical personnel (24 cases, 60.0%); not believing that the screening test could prevent preterm birth (8 cases, 20%) and lack of free drug support for preterm birth prevention in high-risk cases (29 cases, 72.5%). Conclusions: The main obstacles to universal cervical length screening are heavy staff workloads and inadequate government funding for ultrasound scanning and hormone therapy. The healthcare managers do not believe that the universal cervical length screening can help to reduce preterm birth.
其他文献
1 文献来源rnJabbour SK, Lee KH, Frost N, et al. Pembrolizumab plus concurrent chemoradiationtherapy in patients with unresectable, locally advanced,stage Ⅲ non-small cell lung cancer. The phase 2 KEYNOTE - 799 nonrandomized trial[J]. JAMA Oncol,2021,7(9):1-9.
1 文献来源rnTada H, Mitsudomi T, Misumi T, et al. Randomized phase Ⅲ study of gefitinib versus cisplatin plus vinorelbine for patients with resected stage Ⅱ-ⅢA non-small-cell lung cancer with EGFR mutation(IMPACT)[J]. J Clin Oncol,2022,40(3):231-241.
1 文献来源rnWu YL,Tsuboi M,He J,et al. Osimertinib inresected EGFR-mutated non-small-cell lung cancer [J]. N Engl J Med,2020,383(18):1711-1723.rnWu YL,John T,Grohe C,et al. Postoperative chemotherapy use and outcomes from ADAURA:Osimertinib as adjuvant therap
目的 研究4P医学模式在老年高血压护理干预中的应用价值.方法 本次研究对象为2019年9月至2020年9月在本院就诊的老年高血压患者,将108例患者根据随机数字表法进行分组,对照组53例进行常规护理,观察组55例根据4P医学模式进行护理干预.将两组的自我效能评分、治疗依从性、血压水平进行比对.结果 观察组患者干预后的GSES评分、治疗依从性高于对照组,差异具有统计学意义(P<0.05);观察组患者干预后的舒张压、收缩压水平均低于对照组,差异具有统计学意义(P<0.05).结论 4P医学模式指导下的护理干预
1 文献来源rnFelip E,Altorki N,Zhou C,et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage Ⅰ B - Ⅲ A non - small - cell lung cancer (IMpower010):A randomised,multicentre,open-label,phase 3 trial[J]. Lancet,2021,398(10308):1344-1357.rn2 证据
1 文献来源rnHe J,Su C,Liang W,et al. Icotinib versus chemotherapy as adjuvant treatment for stage Ⅱ-ⅢA EGFR - mutant non - small - cell lung cancer (EVIDENCE):A randomised,open-label,phase 3trial[J]. Lancet Respir Med,2021,9(9):1021-1029.rn2 证据水平rn1a.rn3 背 景r
1 文献来源rnForde PM, Spicer J, Lu S, et al. CT003 -Nivolumab(NIVO)+platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) forresectable (ⅠB-ⅢA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial[J]. Cancer Res,2021,81
近年来,肿瘤治疗走向新时代,从靶向及放化疗走向细胞治疗、免疫治疗时代.而2021 年是中国嵌合抗原受体T 细胞疗法(chimeric antigenreceptor T-cell therapy,CAR-T)细胞治疗的元年,有2 个产品被国家药品监督管理局(National MedicalProducts Administration,NMPA)批准应用于临床.2021 年,淋巴瘤的临床研究重点仍聚焦于CAR-T细胞治疗,本文拟对2021 年发表的重磅文章进行综述.
2021年免疫治疗的相关临床研究在各个瘤种中继续遍地开花,而在肿瘤放射治疗领域里,除了免疫治疗的更深入研究,临床研究更关注于放疗剂量、分割模式的优化.
新年的钟声刚刚敲响,回首2021,持续的疫情、低靡的经济均不能阻挡研究者前进的脚步,肺癌领域不断公布令人欣喜的研究成果.rn1 早期非小细胞肺癌(non-small-cell lung cancer,NSCLC)治疗进展rn最 新 版 美 国 综 合 癌 症 网 络(National Comprehensive Cancer Network,NCCN)指南对于可手术的ⅠA期NSCLC患者,优先推荐外科手术切除+淋巴结清扫或取样活检[1].近年来,关于早期患者的放射治疗研究层出不穷,但大体均为不劣性研究,对